Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors

NCT06741644 is registered in ClinicalTrials.gov with CStone Pharmaceuticals as lead sponsor.

NCT NCT06741644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06741644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors
Lead sponsor
CStone Pharmaceuticals
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 24, 2025
Completion date
January 31, 2028
Enrollment
800 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors